• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Teva Pharmaceutical Industries (TEVA) Dropped, So What Is Behind The Latest Attention?

    Simply Wall St·11/03/2026 07:33:18
    语音播报

    Teva Pharmaceutical Industries (NYSE:TEVA) has halted its Phase 2 TOPAS-MSA trial for emrusolmin after an interim futility analysis indicated a low chance of hitting the primary efficacy goal, despite no flagged safety concerns.

    The TOPAS-MSA setback arrived after a strong run for Teva Pharmaceutical Industries, with the share price easing 3.3% over the last session to US$40.70 but still showing a 23.9% year to date share price return and a very large 1 year total shareholder return of 120%, signaling that momentum has been strong even as recent trial and boardroom headlines reshape how investors think about both its opportunity set and risk profile.

    Scan beyond Teva Pharmaceutical Industries and identify other healthcare names that combine strong product pipelines with decisive news flow using our hand picked 33 healthcare AI stocks.

    Teva Pharmaceutical Industries has rallied hard, yet the latest pullback highlights a wide gap between the US$40.70 price, analyst targets and intrinsic value estimates. Where does a fair valuation actually land in that spread?

    Most Popular Narrative: 14% Undervalued

    Teva Pharmaceutical Industries closed at $40.70 while the most widely followed narrative pegs fair value near $47.58, framing the recent pullback as a move that still leaves a sizeable valuation gap on the table.

    The shift in Teva Pharmaceutical Industries toward higher value branded CNS drugs such as AUSTEDO, AJOVY and UZEDY is increasing the share of revenue tied to products that currently carry higher gross margins. Management links this shift to the goal of non GAAP operating margins of 30% and a higher EBITDA contribution over time.

    See why 6 investors see Teva Pharmaceutical Industries as 14% undervalued.

    That fair value view rests on a discount rate of 8.64%, alongside analyst assumptions that Teva Pharmaceutical Industries can support higher profit margins from a larger mix of branded CNS therapies and biosimilars over time.

    The narrative implies that for the $47.58 figure to hold, investors need to be comfortable with earnings reaching about $2.8b by 2029 and the stock trading on a P/E of 26.9x those future profits, compared with a much higher multiple on today’s earnings.

    Analysts contributing to this framework also factor in a forecast profit growth rate of around 30.3% a year, a forecast return on equity that reaches 35% within three years, and a balance sheet that management aims to keep improving from a net debt base of roughly $12.9b.

    At the same time, the narrative highlights that Teva Pharmaceutical Industries still carries a value score of 2 out of 6 and a P/E of 67.2x compared with 16x for the US Pharmaceuticals group. As a result, part of the gap to fair value reflects expectations that margins and earnings will catch up to the current price rather than the current earnings profile alone justifying it.

    Result: Fair Value of $47.58 (UNDERVALUED)

    Still, Teva Pharmaceutical Industries relies heavily on a handful of branded therapies and pipeline milestones, so trial setbacks or weaker than expected launches could quickly challenge this fair value story.

    Find out about the key risks to this Teva Pharmaceutical Industries narrative.

    Next Steps

    With sentiment split between the trial setback and the valuation upside story around Teva Pharmaceutical Industries, it makes sense to move fast. Stress test the thesis against the underlying numbers yourself, then weigh both sides of the ledger by reviewing the 3 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Teva Pharmaceutical Industries?

    Do not stop with Teva Pharmaceutical Industries. Broaden your watchlist with a few targeted starting points that help you focus on clear financial strengths and specific opportunity sets.